UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 110

Sortiert nach

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2604-2611

2010

Link zum Volltext

Verfügbarkeit prüfen

Primary central nervous system lymphoma

Critical reviews in oncology/hematology, 2017-05, Vol.113, p.97-110

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

British journal of haematology, 2015-03, Vol.168 (5), p.654-662

2015

Link zum Volltext

Verfügbarkeit prüfen

Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma

Expert review of neurotherapeutics, 2018-05, Vol.18 (5), p.379-393

2018

Link zum Volltext

Verfügbarkeit prüfen

Present and future treatment options for primary CNS lymphoma

Expert opinion on pharmacotherapy, 2015-11, Vol.16 (17), p.2569-2579

2015

Link zum Volltext

Verfügbarkeit prüfen

R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7575-7575

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Clinical cancer research, 2011-04, Vol.17 (7), p.1964-1972

2011

Link zum Volltext

Verfügbarkeit prüfen

Current uses of radiation therapy in patients with primary CNS lymphoma

Expert review of anticancer therapy, 2013-11, Vol.13 (11), p.1327-1337

2013

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20077-e20077

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20075-e20075

2016

Link zum Volltext

Verfügbarkeit prüfen

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

European journal of cancer (1990), 2010-01, Vol.46 (1), p.198-206

2010

Link zum Volltext

Verfügbarkeit prüfen

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Blood, 2013-11, Vol.122 (21), p.4365-4365

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

European journal of cancer (1990), 2010-10, Vol.46 (15), p.2746-2752

2010

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8035-8035

2013

Link zum Volltext

Verfügbarkeit prüfen

NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7581-7581

2012

Link zum Volltext

Verfügbarkeit prüfen

The primary mediastinal lymphoma: state of the art and therapeutical perspectives

Recenti progressi in medicina, 2013-05, Vol.104 (5), p.203

2013

Link zum Volltext

Verfügbarkeit prüfen

Increased interleukin-10 serum levels in patients with solid tumours

Cancer letters, 1996-06, Vol.104 (1), p.1-5

1996

Link zum Volltext

Verfügbarkeit prüfen

In vivo administration of GM-CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes

Journal of leukocyte biology, 2000-02, Vol.67 (2), p.174-182

2000

Link zum Volltext

Verfügbarkeit prüfen

Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients

International journal of cancer, 2001-03, Vol.91 (5), p.713-717

2001

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial

Tumori, 1998-09, Vol.84 (5), p.534

1998

Link zum Volltext

Verfügbarkeit prüfen

Reduction of Brain Metastasis Following Immunotherapy with Interleukin-2 for Stage IV Renal Cell Cancer

Acta oncologica, 1997, Vol.36 (2), p.228-228

1997

Link zum Volltext

Verfügbarkeit prüfen

Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy

Cancer Immunology Immunotherapy, 1994-05, Vol.39 (3), p.167-171

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(109)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

Primary central nervous system lymphoma

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Risk‐tailored CNS prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma

Present and future treatment options for primary CNS lymphoma

R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial

Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Current uses of radiation therapy in patients with primary CNS lymphoma

Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM)

Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy

Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC)

NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC)

The primary mediastinal lymphoma: state of the art and therapeutical perspectives

Increased interleukin-10 serum levels in patients with solid tumours

In vivo administration of GM-CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes

Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial

Reduction of Brain Metastasis Following Immunotherapy with Interleukin-2 for Stage IV Renal Cell Cancer

Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy

Suchergebnisse filtern